Cargando…

Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance

The epidermal growth factor receptor inhibitor cetuximab is the only oncogene-targeted agent that has been FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC). Currently, there are no biomarkers used in the clinic to predict which HNSCC tumors will respond to cetuximab, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Keefe, Rachel A., Bhola, Neil E., Lee, David S., Johnson, Daniel E., Grandis, Jennifer R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948745/ https://www.ncbi.nlm.nih.gov/pubmed/31914141 http://dx.doi.org/10.1371/journal.pone.0227261

Ejemplares similares

Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC
por: Yao, Yanli, et al.
Publicado: (2022)

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
por: Niehr, Franziska, et al.
Publicado: (2015)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer
por: Bouhaddou, Mehdi, et al.
Publicado: (2021)

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
por: Bray, Steven M., et al.
Publicado: (2019)

PUM1 Is Overexpressed in Colon Cancer Cells With Acquired Resistance to Cetuximab
por: Liu, Qizhi, et al.
Publicado: (2021)

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
por: Johnson, Radia M., et al.
Publicado: (2022)

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
por: Iida, Mari, et al.
Publicado: (2014)

Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
por: Kagohara, Luciane T., et al.
Publicado: (2020)

Correction: Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
por: Kagohara, Luciane T., et al.
Publicado: (2020)

Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis
por: Huang, Jingwen, et al.
Publicado: (2016)

An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation
por: Fu, You, et al.
Publicado: (2020)

Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol
por: Ritter, M., et al.
Publicado: (2016)

Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor
por: Lee, David S., et al.
Publicado: (2018)

NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models
por: Li, Hua, et al.
Publicado: (2022)

Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
por: Osumi, Hiroki, et al.
Publicado: (2013)

PRSS contributes to cetuximab resistance in colorectal cancer
por: Tan, Zhaoli, et al.
Publicado: (2020)

Interplay between Partial EMT and Cisplatin Resistance as the Drivers for Recurrence in HNSCC
por: Ingruber, Julia, et al.
Publicado: (2022)

Drug-adapted cancer cell lines as preclinical models of acquired resistance
por: Michaelis, Martin, et al.
Publicado: (2019)

Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids
por: Klöss, Stephan, et al.
Publicado: (2015)

Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance
por: Tak, Eunyoung, et al.
Publicado: (2022)

Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells
por: Steinbichler, Teresa Bernadette, et al.
Publicado: (2015)

Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes
por: Jubran, Maria R., et al.
Publicado: (2022)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy
por: Zaryouh, Hannah, et al.
Publicado: (2021)

Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
por: Torlot, Lucien, et al.
Publicado: (2022)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer: Correlation between ACAA2 and cetuximab resistance in CRC
por: Yuan, Yitao, et al.
Publicado: (2023)

Cognitive graphs, resistive grids, and the hippocampal representation of space
por: Burgess, N, et al.
Publicado: (1996)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
por: Espinosa-Cotton, Madelyn, et al.
Publicado: (2019)

Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling
por: Chang, Jae Won, et al.
Publicado: (2015)

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
por: De Pauw, Ines, et al.
Publicado: (2019)

Emergence of KRAS p.G13D mutation and acquired resistance to cetuximab in colorectal cancer with vulvar metastasis: A case report
por: Qiang, Weiguang, et al.
Publicado: (2019)

The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines
por: Boeckx, Carolien, et al.
Publicado: (2015)

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
por: Cappuzzo, F, et al.
Publicado: (2008)

Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma
por: Hatakeyama, Hiromitsu, et al.
Publicado: (2010)

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma
por: Braig, Friederike, et al.
Publicado: (2016)

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation
por: Napolitano, Stefania, et al.
Publicado: (2017)

Incidence and survival of HNSCC patients living with HIV compared with HIV-negative HNSCC patients
por: Haase, Katharina, et al.
Publicado: (2021)

Osteopontin Mediates Cetuximab Resistance via the MAPK Pathway in NSCLC Cells
por: Cui, Jian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tuq3emn28k2mtciakqbbh6mejn